On May 7, 2025, Chardan Capital has initiated coverage on Xenon Pharmaceuticals (XENE, Financial) with a "Buy" rating. The analyst behind this coverage is Rudy Li, who has set a price target of $55.00 USD for XENE.
This new coverage and price target provide an optimistic outlook for Xenon Pharmaceuticals (XENE, Financial), reflecting Chardan Capital's positive perspective on the company's prospects.
Investors may find this initiation of coverage as a significant indicator of potential growth for Xenon Pharmaceuticals (XENE, Financial) in the stock market. The absence of a prior rating and price target from Chardan Capital makes this announcement noteworthy.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for Xenon Pharmaceuticals Inc (XENE, Financial) is $56.08 with a high estimate of $65.00 and a low estimate of $42.00. The average target implies an upside of 59.40% from the current price of $35.18. More detailed estimate data can be found on the Xenon Pharmaceuticals Inc (XENE) Forecast page.
Based on the consensus recommendation from 17 brokerage firms, Xenon Pharmaceuticals Inc's (XENE, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Xenon Pharmaceuticals Inc (XENE, Financial) in one year is $0.16, suggesting a downside of 99.55% from the current price of $35.18. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Xenon Pharmaceuticals Inc (XENE) Summary page.
